Genotype-guided drug prescribing vs. usual care reduced clinically relevant adverse drug reactions at 12 wk
- PMID: 37276599
- DOI: 10.7326/J23-0031
Genotype-guided drug prescribing vs. usual care reduced clinically relevant adverse drug reactions at 12 wk
Abstract
Swen JJ, van der Wouden CH, Manson LE, et al; Ubiquitous Pharmacogenetics Consortium. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401:347-356. 36739136.
Conflict of interest statement
Comment on
-
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4. Lancet. 2023. PMID: 36739136 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical